August 7th, MolecularImaging, Kathy Fay Mahdoubi, “Angiogenesis is a hallmark of invasive cancer and antiangiogenesis therapies are gaining momentum, but some patients do not respond well. F-18 FLT may be the strongest contender out of three F-18 labeled PET agents used to evaluate early response to therapy, which aims to improve patient management and negate unnecessary treatments, according to research published August 1 in theJournal of Nuclear Medicine.”